logo-loader

Pattern Pharma looks to raise $15M for its cancer & infectious disease therapy

Published: 09:23 12 Feb 2020 EST

Pattern Pharma CEO Mark de Groot sat down with Proactive’s Christine Corrado at BIO CEO & Investor Conference in New York.

According to the immunotherapy company, its P2PAR product activates the innate immune system to fight infectious diseases and cancers.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 50 minutes ago